IRONWOOD PHARMACEUTICALS INC (IRWD)
IRONWOOD PHARMACEUTICALS INC (IRWD) from its SEC filings: 2025 revenue $296.2 million (-16% vs the year before), net margin 8%, free cash flow $127.0 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $296.2 million |
| Revenue growth | -16% |
| Net income | $24.0 million |
| Net margin | 8.1% |
| Free cash flow | $127.0 million |
| Diluted EPS | $0.15 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +33% |
| Cash | $79.1 million |
| Long-term debt | $199.5 million |
| Share count, 1 year | +2% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.